Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27529191 | 0.86 | SIGMAR1 (0.47) | SIGMAR1CHRM1CCR5KMT2AOPRK1 | |
| SCHEMBL27553023 | 0.86 | SIGMAR1 (0.47) | SIGMAR1CHRM1CCR5KMT2AOPRK1 | |
| SCHEMBL27366961 | 0.86 | CHRM1 (0.54) | SIGMAR1CHRM1CCR5KMT2AOPRK1 | |
| SCHEMBL27366400 | 0.84 | MTNR1A (0.57) | MTNR1AMTNR1B | |
| SCHEMBL27367115 | 0.82 | HCRTR1 (0.41) | SIGMAR1PTGDR2KMT2AMTNR1AMTNR1B | |
| SCHEMBL27367131 | 0.81 | PIN1 (0.40) | SIGMAR1PTGDR2KMT2AMTNR1AMTNR1B | |
| SCHEMBL5235807 | 0.78 | TDP1 (0.45) | PTGDR2KMT2AMTNR1AMTNR1B | |
| SCHEMBL27367140 | 0.76 | HTR2A (0.54) | CHRM1OPRK1MTNR1AMTNR1B | |
| SCHEMBL24821196 | 0.76 | TDP1 (0.64) | PTGDR2KMT2AMTNR1AMTNR1B | |
| SCHEMBL2410035 | 0.76 | TSHR (0.61) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| CN-119384406-A | Compounds of formula (I) | 赛洛私人有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | SIGMAR1 623/4885DPP4 3962/4885DPP9 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.